Author

G. L. Hirst

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:spatial domain detection· 1

Frequent Co-Authors

C. Yau· 2 shared A. Basu· 1 shared A. D. Borowsky· 1 shared A. Demichele· 1 shared A. Glencer· 1 shared A. Officer· 1 shared D. M. Wolf· 1 shared D. Nachmanson· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Yau

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintDec 1, 2023

Tumor microenvironmental determinants of high-risk DCIS progression

A. Glencer, K. Ramalingam, N. Schindler…·A. D. Borowsky

This study identifies immune microenvironment features and myoepithelial continuity as key determinants of progression in high-risk DCIS.

DOI 10.1101/2023.12.01.569676

humanbulk RNA-seq

𝕏 PostBluesky

Cell BiologybioRxivMar 30, 2023

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

K. Yu, A. Basu, C. Yau…·M. Sirota

This study uses computational drug repositioning to identify agents that can sensitize drug-resistant breast tumors, finding fulvestrant effective across multiple treatment and receptor subtypes.

DOI 10.3389/fonc.2023.1192208

humanbulk RNA-seq

𝕏 PostBluesky